Quarterly Updates7 Nov 2025, 06:32 pm
AstraZeneca Pharma India Ltd Marks 37% Growth in Q2, Announces Q2 Results
AI Summary
AstraZeneca Pharma India Limited announced financial results for the quarter ended September 30, 2025. The Company delivered revenue growth of 37% in Q2 FY2025-26, reflecting disciplined execution and momentum across Oncology, Biopharmaceuticals (CVRM, R&I, V&I), and Rare Disease. The financial performance summary and key milestones are detailed in the text.
Key Highlights
- Revenue rises 37% in Q2 2025-26
- Seven new approvals in H1 2025
- Durvalumab received regulatory approval for two additional indications
- Eculizumab launched for the treatment of aHUS and PNH
- Osimertinib received regulatory approval for an additional indication in NSCLC
- Trastuzumab deruxtecan received regulatory approval for an additional indication in HER2-low and HER2-ultralow metastatic breast cancer
- Benralizumab received regulatory approval for an additional indication as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA)